2,400
Participants
Start Date
July 1, 2019
Primary Completion Date
June 30, 2022
Study Completion Date
June 30, 2034
Renin-angiotensin-aldosterone system inhibitors
Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Beta blocker
Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
RECRUITING
Singapore General Hospital (SGH), Singapore
Singapore General Hospital
OTHER
Mackay Memorial Hospital
OTHER
National Taiwan University Hospital
OTHER
Peking University People's Hospital
OTHER
Medanta, The Medicity, India
OTHER
Public Health Foundation of India
OTHER
Putrajaya Hospital, Malaysia
UNKNOWN
Universiti Teknologi Mara
OTHER
National Heart Centre Singapore
OTHER